Dwight Gardiner, a Summerside, P.E.I. man who has been living with cancer since 2018, says the Canadian health-care system is ...

Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal ...

Already, stem cells have been able to help people with conditions like testicular cancer, leukemia, aplastic or refractory anemia, osteoporosis, multiple myeloma, and a group of blood diseases ...

Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't ...

During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to ...

Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

Annual whole-body, low-dose computed tomography (WBLDCT) can improve the management of smoldering multiple myeloma (SMM), ...

The findings, which were presented at the 50th Annual Oncology Nursing Society Congress, showed that at a median follow-up of ...

Data from the CEPHEUS trial support the use of D-VRd in patients with transplant-ineligible or -deferred multiple myeloma who can tolerate bortezomib ... D-VRd led to a significant 43% reduction in ...

Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its ...